.Attributes Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint asks for addition of clients along with MASLD and measurement of liver results in cardio-- kidney-- metabolic trials, when data recommend mechanistically plausible advantages and scientific security-- and also details factors to consider for trial design as well as regulative commendation.